Iceland· IS-EU/1/12/793/006
XALKORI
A crizotinib product containing crizotinibum inn, registered in Iceland by Pfizer Europe MA EEIG*. The same ATC class is registered in 13 of our 19 countries.
Checked against Icelandic Medicines Agency (Iceland) on
Informational only — not a medical device.
Where it is registered
Crizotinib is registered in 13 of 19 countries.
Countries holding a registration under ATC L01ED01 (crizotinib), each read from that country’s own register.
- This record: Iceland, from Icelandic Medicines Agency (Iceland)
- 8 of them publish a price we can compare per daily dose
Crizotinib · ATC L01ED01
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of crizotinib costs, country by country.
Normalised to the WHO defined daily dose (0.5 g), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Crizotinib · price per daily dose (0.5 g)
USD · FX 28 Sept 2026
- CH Switzerland$203.81
The record
At a glance
Icelandic Medicines Agency (Iceland)- Active substance
- Crizotinibum INN
- Manufacturer
- Pfizer Europe MA EEIG*
- Country
- Iceland (IS)
- ATC code
- L01ED01
- ATC class
- Crizotinib
- Defined daily dose
- 0.5 g, O
- Reimbursed
- Not published by this register
- Source register
- Icelandic Medicines Agency (Iceland)
- Last checked
- September 29, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
681 interactions on record for crizotinib.
Graded by severity as the source publishes them — 326 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Crizotinib · interactions on record
681 records
- 326 severe
- 338 moderate
- 17 minor
Most severe, free to view
- PapaverineA03AD01severe
- CisaprideA03FA02severe
- OndansetronA04AA01severe
- GranisetronA04AA02severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Crizotinib in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaXALKORIPfizer Europe MA EEIG, Bruxelles
- SpainXALKORI 50 MG GRANULADO EN CAPSULAS PARA ABRIRPfizer Europe Ma Eeig
- FinlandXALKORIPfizer Europe MA EEIG
- PolandXalkoriPfizer Europe MA EEIG
- SwedenXALKORI 50 mg Granulat i kapsel avsedd att öppnasPfizer Europe MA EEIG
- United StatesXalkoriPfizer Laboratories Div Pfizer Inc
- SwitzerlandXalkori 150 mg, filmüberzogenes Granulat zum EinnehmenPfizer AG
- United KingdomXalkori 200mg capsulesPfizer Ltd
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Liechtenstein · Xalkori
- Norway · Xalkori
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Icelandic Medicines Agency (Iceland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/94a6db1c-33fe-4197-8167-737dfe1b6198 GET /v1/drugs/94a6db1c-33fe-4197-8167-737dfe1b6198?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Kyrni í hylki sem á að opna",
"source": "lyfjastofnun",
"atc_raw": "L01ED01",
"marketed": false,
"strength": "50 mg",
"ma_number": "EU/1/12/793/006",
"substance": "Crizotinibum INN",
"other_info": "Ávísun lyfsins er bundin við sérfræðinga í blóðsjúkdómum, krabbameinslækningum og blóðsjúkdómum og krabbameinslækningum barna.\r\nMarkaðssetning á Íslandi er háð því að Lyfjastofnun hafi staðfest að sérstök skilyrði er varða öryggi og verkun við notkun lyfsins séu uppfyllt.",
"legal_status": "(R Z) Sérfræðingsmerkt (og lyfseðilsskylt)",
"ma_issued_serial": "45526"
}See everything about crizotinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.